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Abstract
Tumor necrosis factor alpha (TNF alpha) inhibitors are widely and effectively 
used for inflammatory and autoimmune diseases in rheumatology, gastroenterol-
ogy, and dermatology. Adalimumab, etanercept, and infliximab are indicated for 
the treatment of patients with moderate to severe chronic plaque psoriasis. This 
target treatment is very effective and lead to control the most severe cases, which 
were formerly fatal. Biologic treatment is strictly monitored. These large molecules, 
even with the same mechanism of action in the form of inhibiting TNF alpha, may 
act differently, and they may have other adverse effects. Skin complications of anti-
TNF alpha treatment include a wide range of manifestations which can be divided 
into four groups: infections, reactions directly associated with drug administration, 
immune-mediated skin reaction, and malignancy. This chapter describes currently 
available information regarding the occurrence of individual complications and 
defines possible therapeutic options in case of individual adverse reactions.
Keywords: anti-TNF alpha, adverse reactions, infection, drug-related reactions, 
immune-mediated reactions, malignancy
1. Introduction
Tumor necrosis factor alpha (TNF alpha) inhibitors have been successfully used 
in the treatment of various immune-mediated inflammatory diseases since the early 
1990s. In dermatology, chronic plaque psoriasis is treated by three biologics belong-
ing to the group of TNF alpha inhibitors: infliximab, adalimumab, and etanercept.
Biologic therapy offers new treatment options for psoriatic patients with high 
levels of efficacy and convenience; such treatments have immunomodulatory or 
immunosuppressive effects that may predispose patients to potential adverse events 
[1–4]. The skin is one of the most frequently affected organs. Adverse effects of 
anti-TNF alpha on the skin represent nearly 25% of all adverse effects [5, 6]. Despite 
the strict observation of preclinical studies, many adverse effects were manifested 
only following the implementation of biologics in clinical practice. In 2004, a paper 
on anti-TNF alpha treatment-induced psoriasis was first published [7]. Since then, 
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a whole group of so-called immune-mediated adverse effects which includes a 
large group of so-called paradoxical reactions has emerged. Likewise, new cases 
of hypersensitivity reactions continue to arise with ambiguous pathogenesis. Skin 
complications of anti-TNF alpha treatment include a wide range of manifestations 
which can be divided into four groups: skin infections, reactions related with drug 
administration, immune-mediated reactions, and malignancies (Table 1). In this 
chapter, we describe currently available information regarding the occurrence of 
individual complications and define possible therapeutic approach in the case of 
individual adverse reaction necessary for such adverse reaction to be resolved.
2. Infections
Early randomized and postmarketing studies proved that patients undergoing 
anti-TNF alpha therapy are at increased risk of infectious diseases namely, bacterial, 
viral, fungal, and opportunistic [8]. Data from the British and German rheumatol-
ogy registry confirm that the skin is the second most common location of serious 
infections, immediately after the respiratory system [9–11]. Besides other risk 
factors which may impact the onset on infections, combined immunosuppressive 
treatment, which increases the number of infectious complications, is regarded as 
the most significant. The majority of skin infections are nonserious adverse effects 
that go unreported in studies and registries but which nevertheless cause problems 
to patients and may have a fundamental impact on their quality of life. Infectious 
skin complications can be divided into three groups:
• Viral infections
• Bacterial infections
• Fungal infections
2.1 Viral infections
2.1.1 Herpes infections
Herpes infections are the most common viral complications. According to reg-
istries and article reviews, the incidence of reactivated herpes infections in patients 
on anti-TNF alpha therapy is around 1–5% [5, 12, 13].
2.1.1.1 Varicella-zoster virus
Varicella-zoster virus (VZV) reactivation and occurrence of herpes zoster infec-
tion is a common serious adverse event. According to Burmester et al., the incidence of 
Skin adverse reactions
1. Skin infections
2. Reactions directly associated with drug administration
3. Immune-mediated skin reactions
4. Malignancy
Table 1. 
Classification of skin adverse reactions.
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herpes zoster (HZ) infection in a group of 23,458 patients treated with adalimumab in 71 
studies of dermatological, rheumatological, and gastrointestinal indications is 0.3/100 
patient-year (PY) [14]. Yet in contrast, one of the most recent publications regarding the 
long-term follow-up of psoriatic patients did not confirm the association of increased 
HZ risk in patients treated with ustekinumab, TNF alpha inhibitors, and methotrexate. 
However these authors also stated that a larger number of HZ events would be needed to 
assess the presence or absence of risk [15]. In the case of the VZV infection, early diag-
nosis and timely treatment are a precondition for the prevention of VZV complications. 
Most feared complications include meningoencephalitis, myositis, pneumonitis, hepa-
titis, and herpes zoster ophthalmicus. The most frequent complication is postherpetic 
neuralgia. Caution is required in patients on combined immunosuppressive treatment, 
in whom the disease may take a severe course. In the case of a localized infection, oral 
virostatic agents are the treatment of choice (Table 2). Disseminated herpetic  
manifestations require patient hospitalization in order to administer intravenous 
treatment. Biologic treatment is immediately suspended due to the severity of herpes 
infection. Further doses of biologics are never administered in the acute stage of the 
disease. Biologic agents are subsequently not contraindicated, and biological treatment 
may continue after the complete return of body temperature to normal and the sup-
pression of skin manifestations. Primary VZV infection is very dangerous in patients on 
anti-TNF alpha and may take a very complicated course. Vaccination is recommended in 
patients who failed to previously overcome VZV, which must be administered 3 weeks 
before the initiation of biologic therapy at the latest [16]. If the patient contracts a 
primary VZV infection, it is necessary to immediately suspend anti-TNF alpha therapy 
and initiate treatment with aciclovir 10 mg/kg every 8 h for at least 7 days (Figure 1).
Complicated cases require diagnostic examinations. Serologic tests are most important 
for the diagnosis of previous disease and also at the acute stage. PCR, viral culture, and 
IHC or hybridization methods are more sensitive for the confirmation of a diagnosis of 
current VZV infection or reactivation in the event of clinical uncertainty [16].
Infection Treatment
HSV1, HSV2
Mucocutaneous disease p.o. Aciclovir 400 mg 3 times a day
p.o. Famciclovir 500 mg 2 times a day
p.o. Valaciclovir 1000 mg 2 times a day
Duration until complete healing of lesions occurs
Disseminated disease i.v. Aciclovir 5–10 mg/kg every 8 h
Prophylaxis p.o. Aciclovir 400 mg 3 times a day
p.o. Famciclovir 500 mg 2 times a day
p.o. Valaciclovir 1000 mg 2 times a day
Duration at least 1–3 months
Herpes zoster—VZV
VZV localized Aciclovir 800 mg 5 times a day
Brivudin 125 mg once a day
Famciclovir 500 mg 3 times a day
Valaciclovir 1000 mg 3 times a day
Duration until complete healing of lesions occurs
VZV disseminated or visceral i.v. Aciclovir 5–10 mg/kg every 8 h
Duration until complete healing of lesions occurs, usually 7–10 days
VZV primo infection i.v. Aciclovir 5–10 mg/kg every 8 h
Duration until complete healing of lesions occurs, usually 7–10 days
Table 2. 
Management of herpesvirus infections in patients on anti-TNF alpha treatment (adapted from [16, 17]).
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2.1.1.2 Herpes simplex virus (HSV)
Herpes simplex virus 1 (HSV1) and herpes simplex virus 2 (HSV2) herpes infec-
tions are a relatively frequent complication which may if recurrent impact patient 
quality of life. Due to the relatively benign course of HSV infections, the majority 
are not recorded in registries—hence the limited data on incidence in patients on 
anti-TNF alpha therapy. Our experience with 1 year follow-up of skin viral infection 
in 239 psoriatic patients taking anti-TNF alpha confirms 12 cases with HSV 1 and 
HSV2 infection, which is incidence 5,0/100 PY.
In the general population, an occurrence of more than five episodes a year is 
regarded as a recurrent HSV infection that initiates prophylactic virostatic therapy. 
Repeated or disseminated infection in patients on anti-TNF alpha therapy is an 
indication for prophylactic treatment (Table 2). In adult patients, acute primary 
infections are not encountered which may be manifested as herpetic gingivostoma-
titis. In the majority of herpes simplex labialis infections, anti-TNF alpha therapy is 
not suspended. If the disease has a more severe course, therapy is suspended until 
the suppression of skin or system manifestations [16]. HSV1 and HSV2 are only 
diagnosed in clinically unclear manifestations.
2.1.2 Other viral infections
The manifestation of clinical skin human papillomavirus (HPV) infection 
during anti-TNF alpha therapy is frequent. HPV and molluscum contagiosum (MC) 
viral proteins seem to interfere with the apoptotic pathway of the host cell signaled 
by TNF receptors. Anti-TNF alpha agents block TNF directly, so HPV and MC could 
develop or flare [18].
Clinically, HPV infection is manifested as verrucae vulgaris and condylomata 
acccuminata. When treating condylomata accuminata, we avoid topical treat-
ment with imiquimod, since this may induce the formation of psoriatic lesions or 
psoriasis-like plaque.
2.2 Bacterial infections
Erysipelas and cellulitis are common severe skin bacterial complications. 
Cellulitis is one of the most common infectious skin diseases that occur in the 
course of biological therapy (0.3/100 PY). The first manifestations of cellulitis and 
Figure 1. 
Female patient treated for seropositive RA and psoriasis with combination therapy: anti-TNF alpha inhibitor, 
methylprednisolone 4 mg, and methotrexate 7.5 mg. Acute hospitalization for extensive herpes zoster in 
dermatome S2, S3 on the left (6 days after the first disease manifestations). A gynecologist was consulted on 
the first day of symptoms; on the fourth day, the patient was examined in an emergency room due to urine 
retention, with permanent catheter insertion and the initiation of oral virostatic therapy which, however, 
was ineffective. During hospitalization, the patient received 3 × 500 mg aciclovir i.v. for 10 days, followed by 
3-month prophylaxis. The disease was complicated by neuralgia and temporary defecation disorder.
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erysipelas require immediate antibiotic treatment. These data have been confirmed 
not only in all patients (rheumatological, gastroenterological, and dermatologi-
cal) undergoing anti-TNF alpha therapy [14]. The early initiation of therapy may 
prevent subsequent complications. If the disease is resistant to the oral form, intra-
venous antibiotic treatment or sometimes combined therapy is initiated. In the case 
of acute manifestations of the disease, biological therapy is suspended immediately. 
After the successful treatment of an acute attack, long-term antibiotic prophylaxis 
may continue.
As stated by Andrade et al., bacterial infections were most frequent when 
observing adverse effects in patients with inflammatory bowel disease (IBD) (732 
patients, 10-year follow-up) on anti-TNF alpha therapy, accounting for 45% of all 
infections. Most common were folliculitis in 38% of patients and abscesses in 31%. 
Psoriatic patients are likely to have less abscesses, since IBD diseases have specific 
extraintestinal manifestations and are also associated with hidradenitis suppurativa 
comorbidity which may be evaluated as folliculitis and abscesses [19].
2.3 Fungal infections
Fungal infections are not as frequent as viral and bacterial infections. Likewise, 
such depend on whether the patient is on combined immunosuppression. In the 
case of opportunistic infections, association between anti-TNF alpha and oral 
candidiasis has been described but only in a very small number of cases (less than 
0.1 patient per 100/PY). Cases of esophageal candidiasis have occurred in particular 
in patients with Crohn’s disease (CD). Rare cases of aspergillosis, candida sepsis, 
and coccidioidomycosis have been reported [14]. To a large degree incidence is 
impacted by concurrent systemic corticosteroid treatment, which is not indicated 
for the treatment of psoriasis [20]. In practice we can observe cases of tinea pedis 
and onychomycosis, which are also very common in the general population; data on 
comparison of incidence with the general population are very limited. If joints are 
severely affected by psoriatic arthritis with deformation of toes, interdigital fungal 
manifestations are more common. Treatment of the fungal infection is essential in 
prevention of skin cracking, which is a portal for the entry of bacterial infections. 
Figure 2. 
Female patient treated with adalimumab, who was working as a nurse at a psychiatric department. A 
follow-up examination revealed green-brown nail color (A). Culture test findings: Pseudomonas aeruginosa ++, 
Klebsiella pneumoniae +, Kocuria kristinae ++, Candida albicans ++, Candida tropicalis +. Topical antibiotic 
treatment in combination with antimycotic therapy was initiated. (B) Condition after 6 weeks of treatment.
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Superficial skin mycoses in patients on anti-TNF alpha therapy may be mistaken for 
psoriasis, and if such occur following anti-TNF alpha therapy, they may be mistaken 
for paradoxically induced psoriasis. In complicated cases, it is therefore necessary to 
conduct a direct microscopic and culture fungal examination (Figure 2).
3. Reactions directly associated with therapy administration
Reactions associated with therapy administration have a heterogeneous nature. 
Their classification and etiopathogenesis are complicated. Due to the different 
structure and properties of anti-TNF alpha preparations, reactions are described 
separately for infliximab, adalimumab, and etanercept.
3.1 Infliximab
Most data in literature and reactions following administration are associated 
with infliximab. Infliximab is a chimeric monoclonal antibody (murine/human) 
of immunoglobulin (Ig) G1 class anti-TNF alpha. Due to its chimeric element and 
intravenous administration, patients are premedicated prior to therapy.
Acute reaction to infusion occurs in 10–40% of infliximab-treated patients 
and usually starts during administration or within an hour of administration of 
the biologic agent. Delayed reaction to infusion occurs in 1–14 days following 
the administration of the biologic agent and is typically associated with myalgia, 
arthralgia, headache, rash, and fatigue. In some cases, a serum sickness-like reac-
tion develops [21, 22]. According to FDA data and post-marketing surveillance, this 
reaction occurs in 2% patients.
Acute reactions can be divided into mild, moderate, and severe. Mild and 
moderate reactions may be dealt with by slowing the infusion rate or momentary 
interruption or infusion, with symptoms spontaneously resolving. Clinical mani-
festation is accompanied by headache, itching, nausea, and erythema [21, 22].
Severe forms of acute reactions are described in 5% cases, with manifesta-
tions of severe anaphylactic reaction [21]. Treatment must be suspended and 
readministration of the biologic agent is not recommended. It is assumed that 
the reaction is not a standard anaphylactic reaction, but rather an anaphylactoid 
one. In recent years, many papers describing the formation of antibodies against 
biologic agents have been published. The formation of antibodies against biolog-
ics is called immunogenicity of biological treatment and is associated with acute 
reactions. Steenholdt et al. evaluated the formation of antibodies against inf-
liximab and the formation of IgE antibodies during acute reactions. Their work 
confirmed that serious acute reactions following infliximab are closely associated 
with the production of anti-IFX IgG antibodies while having no relation to anti-
IFX IgE antibodies. The reactions are therefore not called anaphylactic but rather 
anaphylactoid. In the observed set, reactions occurred most frequently with 
second administration. Low levels of anti-IFX IgG antibodies prior to subse-
quent administration do not exclude the possibility of reaction [23]. In contrast, 
works confirm the association between the occurrence of acute reactions and 
specific IgEs against a biologic agent [24, 25]. Likewise, works have successfully 
implemented desensitization with a biologic agent following acute urticarial and 
anaphylactic reaction [26].
While the precise mechanisms of individual reactions have not been explained, 
it transpires that monitoring the formation of antibodies against biologics may 
be important to differentiate certain reaction types. In daily practice it has 
become common to administer combined suppressing biologics with low doses of 
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methotrexate or in the case of chronic inflammatory bowel disease in combination 
with azathioprine. Combined suppression should reduce the formation of antibod-
ies against biologics and thus reduce adverse reactions [27].
3.2 Adalimumab
Adalimumab is a recombinant human high-affinity immunoglobulin G1 (IgG1) 
monoclonal antibody that inhibits TNF alpha. A reaction at the injection site is 
most frequent, which may occur after administration or within 1–2 days and usually 
resolves within 3–5 days. It occurs in nearly 20% of patients, and occurrence is 
much less frequent compared to etanercept [28]. Anaphylactic and anaphylactoid 
reactions are rare.
Benucci et al. also described a case of an immediate systemic reaction to adalim-
umab with positive skin prick and intradermal tests. Nevertheless, serum-specific 
IgE to adalimumab results were not detectable. This was the first case of immuno-
logic but not IgE-mediated immediate systemic reaction to adalimumab [29].
3.3 Etanercept
Etanercept is a dimeric human recombinant protein constituted by the bind-
ing of two soluble TNF receptors (p75 and human IgG1 Fc). It binds irreversibly 
and competitively to circulating and membrane-bound TNF-α and TNF-β, thus 
preventing its interaction with membrane receptors of effector cells of the immune 
system [30]. According to the Food and Drug Administration (FDA), up to 37% of 
patients have injection site reaction to etanercept, while other types of reaction are 
rare with this biologic agent [31]. As described in the case of adalimumab, the reac-
tion resolves within several (3–5) days. Most of these reactions are type IV delayed-
type hypersensitivity (DTH) reactions [31]. Benucci et al. described two cases of 
etanercept-induced ISR consisting of edema, erythema, and itching [29]. In both 
patients, intradermal tests with etanercept were positive at the immediate reading 
and negative at the later reading, suggesting an immediate reaction, possibly IgE-
mediated (“Type I” reaction).
Borrás-Blasco et al. and Skyttä et al. described three cases of severe urticaria 
induced by etanercept [32, 33]. Although the overall risk of urticaria appears low, 
clinicians should be aware of this reaction.
3.4 Testing and invoking tolerance
Due to various mechanisms of injection site reactions, as well as anaphylactic or 
anaphylactoid reactions, it is appropriate to supplement patient testing.
Literature contains publications which describe various protocols for the dilu-
tion of biologic agents when testing using prick and intradermal tests; some authors 
have also conducted patch tests [30, 34].Likewise, various procedures invoking 
drug tolerance and the detection of antibodies against biologics from IgG and IgE 
class are becoming more available. In the case of serious reactions, it is preferred 
to switch biological therapy prior to desensitization, which is only carried out in 
exceptional cases when there is no other therapeutic modality available.
4. Immune-mediated complications
As we mentioned at the beginning, immune-mediated adverse effects are a new 
group of diseases. We recently published a chapter on immune-mediated adverse 
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effects, analyzing pathogenesis and reactions in all indications of anti-TNF alpha 
therapy [35]. The following section is therefore only about diseases that occur 
in psoriasis patients on anti-TNF alpha therapy, followed by a description of the 
potential therapeutic procedures in the event of immune-mediated complications.
4.1 Psoriasis
Psoriasis or psoriasiform reaction is one of the most common immune-mediated 
reactions. This reaction may occur in psoriasis patients successfully treated with 
anti-TNF alpha therapy. The formation of anti-TNF alpha-induced psoriasis is also 
called a paradoxical reaction. Psoriasis or psoriasiform reaction is one of the most 
common immune-mediated reactions.
The clinical symptom of paradoxical psoriasis can be of variable nature. 
Paradoxical psoriasis includes newly developed psoriasis as well as the signifi-
cant worsening of existing psoriasis. The disease is most commonly manifested 
in the palms and soles as palmoplantar pustulosis reported in 56% of cases; 
other common forms include chronic plaque psoriasis (50%) and guttate 
manifestations (12%). Patients may also suffer from multiple forms of disease 
simultaneously (15%) [36]. Other manifestations include scalp or nail involve-
ment. The clinical picture of the disease in patients with chronic plaque psoriasis 
most often includes the formation of palmoplantar pustulosis, which they did 
not suffer before (Figures 3 and 4). While the pathogenic mechanism of this 
paradox reaction remains unclear, the most widespread theory links the relation-
ship between TNF alpha and type 1 interferon alpha: TNF alpha blockers can 
lead to the overproduction of INF-alpha. In papers that confirm this theory, 
the increased expression of interferon alpha was demonstrated in skin biopsy 
compared to common psoriatic findings [37]. One of the latest theories involves 
the Th 17 pathway. TNF alpha inhibitor may cause dysregulation in the immune 
system, which may cause the following changes. We describe possible therapeu-
tic approaches in patients with psoriasis and paradoxical reactions in Figure 5.
4.2 Alopecia areata
Etiopathogenesis of alopecia areata is not clear. Some authors explain the 
occurrence of alopecia areata similar to TNF alpha-induced psoriasis. Inhibition 
of TNF alpha results in dysregulation of cytokines and subsequent production of 
IFN-alpha, which results in a pathological process [38].
Alopecia areata could be solitary finding or could accompany other immuno-
logically mediated reaction. In practice we can see that alopetic lesions can regress 
Figure 3. 
Patient with positive family history for psoriasis with palmar ragadiform eczema, nail lesions, and erythema 
around wrist. Lesions started immediately after 1 month of initiation adalimumab therapy sent to our 
department like paradoxical psoriatic reaction. Fungal culture proves Trichophyton rubrum.
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to normal, even without biologic agent discontinuation or switching. Along with 
biologic treatment, local treatment or cyclosporin can be added to the treatment 
regime to manage less severe cases of alopecia areata. In cases which lead to gen-
eralized or universal alopecia, immediate biologic treatment discontinuation is 
indicated. Corticosteroid pulses are not recommended due to possible rebound of 
primary disease [35].
Figure 4. 
(A) Patient in whom palmoplantar pustular reaction with concomitant alopecia areata started 2 months 
after adalimumab treatment initiation for chronic plaque psoriasis. In the time of adverse event, the patient 
was already without chronic plaque psoriasis. Discontinuation of anti-TNF alpha and switch to secukinumab 
resolve skin reactions (B).
Figure 5. 
Therapeutic algorithm in management of paradoxical psoriasis in patients with psoriasis on anti-TNF alpha 
treatment.
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4.3 Sarcoidosis
Literature data indicate a possible occurrence of sarcoidosis in 0.04% of the 
patients treated with TNF alpha inhibitors [39]. The skin symptoms were manifested 
as erythema nodosum, pigmented scars, and nodular lesions [40]. Differential 
diagnosis of symptoms along with histological examination is important (Figure 6). 
In most cases, the anti-TNF alpha agent was discontinued. Rechallenge was not 
performed, but a limited number of patients switched therapy without relapse.
4.4 Other reactions
A wide range of skin immune-mediated adverse reactions have been described 
in relation with using anti-TNFα agents. Frequently reported reactions are vascu-
litis, lupus-like syndrome, vitiligo, lichen and lichenoid reaction, and hidradenitis 
suppurativa. Some cases reports about pyoderma gangrenosum, morphea, and 
dermatomyositis induced by anti-TNF alpha agents [35].
5. Malignancy
Many studies examining the carcinogenic risk of TNF-α inhibitors suggest that 
they can slightly increase the risk of cancer, mainly non-melanoma skin cancer 
(NMSC).
In their summary work, Burmester et al. assessed the incidence of malignancies 
in patients treated with adalimumab against the general population. Overall, the 
incidence of malignancies in patients undergoing biologic therapy with adalimumab 
was comparable to the general population. A higher incidence of non-melanoma 
skin cancer (NMSC) compared to the general population in all indications of 
the biologic agent was also unconfirmed. The occurrence of melanoma was not 
significantly higher vs. the general population [14]. A recent meta-analysis of 77 
Figure 6. 
Patient on adalimumab therapy with five small granulomatous lesions which developed during 3 months after 
treatment initiation of adalimumab. Patient had before etanercept. Histologic examination revealed skin 
sarcoidosis; pulmonary sarcoidosis was subsequently confirmed by pulmonary examination. Anti-TNF alpha 
agent was discontinued.
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randomized controlled trials of adalimumab, infliximab, and etanercept associated 
with all anti-TNF alpha therapies for NMSCs was 2.02 [41].
The risk of melanoma with TNF inhibitors is controversial. The meta-analysis of 
registries found increased but insignificant risk of developing melanoma in patients 
treated with anti-TNF, because the pooled estimate from two studies was 1.79 (95% 
CI, 0.92–2.67). In addition, a combined analysis of 11 European registries did not 
find any increased risk of melanoma with anti-TNF [42].
Comparisons of biologic agents and malignancies in patients with psoriasis 
are included in outputs from the PSOLAR database (long-term follow-up, 12,000 
psoriasis patents), with higher incidence of malignancies detected in the case of 
infliximab vs. adalimumab and etanercept [43]. When assessing cancer diseases, we 
have to consider the potential previous combined immunosuppression that patients 
may already receive (Figure 7). We know that most patients on biological therapy 
previously received high doses of conventional immunosuppressive systemic 
therapy, and in psoriasis patients we have to take into account the impact of photo-
therapy as well. HPV infection is a factor which may contribute to the development 
of squamous cell carcinoma.
All patients on anti-TNF alpha therapy should be regularly (annually) monitored 
for skin changes and undergo examination prior to the initiation of anti-TNF alpha 
therapy. Patients should use appropriate photoprotection and be advised of poten-
tially increased risk of NMSC. In the case of a newly detected NMSC, the removal 
of skin cancer is recommended in most cases with the subsequent continuation of 
biologic therapy. We do not recommend the application of topical imiquimod, which 
may induce the formation of psoriatic lesions. In psoriasis patients, it is sometimes 
difficult to distinguish between a superficial basocellular carcinoma and a psoriatic 
lesion. So if a psoriatic lesion is refractory to topical treatment, we have to consider a 
potential superficial basal cell carcinoma as part of differential diagnostics.
In the case of squamous cell carcinoma, the staging and grading of the carci-
noma should be reviewed, and subsequently consider whether biological therapy 
should continue. Alternatives would be systemic retinoids [44].
6. Conclusion
Biologic therapy with anti-TNF alpha agents is a first-line and highly effective 
biologic therapy of psoriasis but is commonly associated with complications and 
adverse events. In the case of long-term, lifelong therapy, such events can be seen 
Figure 7. 
Squamous cell carcinoma developed 3 months after traumatic injury from small erosion. Patient with severe 
chronic plaque psoriasis treated with multiple systemic and multiple biologic therapies efalizumab and 
etanercept, and the last biologic agent was ustekinumab. Ustekinumab was discontinued.
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in almost every patient. The correct management of an adverse effect may prevent 
subsequent complications or the avoidable switching to another biologic prepara-
tion—if a biologic agent is highly effective for an underlying psoriatic disease, we 
continue its use for as long as possible. Every other biologic agent is less effective 
than in a naive patient. In contrast, the abrupt termination of biologic therapy may 
protect from potential and even fatal complications. Therefore, collecting informa-
tion on the incidence of individual adverse effects, even minor ones, but which have 
a significant impact on quality of life and the optimum handling of such effects, is 
crucial for long-term biologic therapy.
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